Blockade D1-like and D2-like dopamine receptors within nucleus accumbens attenuate hyperalgesia responses in a 6-OHDA induced parkinson’s disease rat model
Objective: To investigate the role of blockade D1-like and D2-like dopamine receptors within nucleus accumbens attenuate hyperalgesia responses in a 6-OHDA induced parkinson’s disease rat…STN DBS – A study of frequency of gait (fog) in Parkinson’s disease
Objective: In search of new techniques to help improve lifestyle of Parkinson`s diseased conditions (PDs), a wireless technique is proposed to identify freeze, reduce freeze,…Self-rated burden grading of nonmotor symptoms identifies landmarks and subtypes of Parkinson’s disease: first report from a Moscow-Madrid-London collaboration
Objective: To describe clinical and imaging biomarkers of nonmotor symptoms burden (NMSB) as defined by NMS questionnaire (NMSQ) scores in a prospective international cohort study…D2 receptor mediated DARPP32/PP1α signaling is responsible for cadmium induced Parkinson’s like behavioral alterations in rats
Objective: To identify the specificity of dopamine D2 receptor mediated signaling in cadmium mediated motor alterations Background: Cadmium, a heavy metal, is to known to…DaTscan in clinical evaluation of Multiple System Atrophy
Objective: To explore accuracy of DaTscanTM Ioflupane I123 Injection (DaTscan) in a multiple system atrophy (MSA) cohort Background: There are isolated cases of normal DaTscan in neuropathologically confirmed MSA-cerebellar subtype (MSA-C)…99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson’s disease.
Objective: In this study we tried to determine the TRODAT SPECT findings in EOPD as compared to LOPD. Background: 99mTc-TRODAT-1, which binds to the dopamine…Clinical Utility of Optimized Parameters for a Quantitative Analysis of 123I-ioflupane SPECT (DaTscan) Images
Objective: Validate an automated analysis of DaTscan SPECT images on a representative cohort of patients for discriminating between Parkinson's Disease (PD) versus non-PD. Background: Quantitation…Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium
Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…Patterns of Striatal DAT Binding Loss in a Progressing Parkinson Disease (PD) Cohort: Four year PPMI Follow-up
Objective: To evaluate within subject striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants studied over four years in the…PET examination of the monoamine transporter with 11C-beta-CIT
Objective: To investigate the utility of 11C-β-CIT PET scan on Parkinson's disease diagnosis. Background: The monoamine reuptake sites transport dopamine, noradrenaline and serotonin from the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.